# Radiopharm Theranostics Ltd: overview RADX · Nasdaq · CIK 1949257 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/radx.md) · [Financials](/companies/radx/financials.md) · [Filings](/companies/radx/filings.md) · [Insiders](/companies/radx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2023-06-30) | FY (2024-06-30) | FY2025 (2025-06-30) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [0.3](/filings/0001213900-25-088699.md) | [0.3](/filings/0001213900-25-088699.md) | [3.6](/filings/0001213900-25-088699.md) | | Gross margin | % | [100.0%](/filings/0001213900-25-088699.md) | [100.0%](/filings/0001213900-25-088699.md) | [1.1%](/filings/0001213900-25-088699.md) | | Operating margin | % | [(11796.1%)](/filings/0001213900-25-088699.md) | [(15777.2%)](/filings/0001213900-25-088699.md) | [(1050.6%)](/filings/0001213900-25-088699.md) | | Net margin | % | [(11838.6%)](/filings/0001213900-25-088699.md) | [(16024.3%)](/filings/0001213900-25-088699.md) | [(1055.3%)](/filings/0001213900-25-088699.md) | | Diluted EPS | $ per share | [(11.32)](/filings/0001213900-25-088699.md) | [(12.41)](/filings/0001213900-25-088699.md) | [(1.76)](/filings/0001213900-25-088699.md) | | Free cash flow | $m | [(23.2)](/filings/0001213900-25-088699.md) | not reported | not reported | - Revenue. XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:RevenueFromContractsWithCustomers; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/radx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $670.5k | 51,000,000 | | Unchanged | | [HSBC HOLDINGS PLC](/funds/873630.md) | 2026-06-30 | $253.7k | 62,188 | | Added +816 | | [Regal Partners Ltd](/funds/1577774.md) | 2026-06-30 | $168.2k | 40,138 | | Unchanged | | [PNC Financial Services Group, Inc.](/funds/713676.md) | 2026-06-30 | $83.8k | 20,000 | | Added +4,000 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $6.3k | 1,507 | | Reduced −1,493 | | [Integrated Wealth Concepts LLC](/funds/1737109.md) | 2026-06-30 | $5.5k | 1,310 | | New +1,310 | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $817 | 195 | | Added +74 | ## Recent filings [All 156 filings](/companies/radx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 08:00 ET | [6-K](/filings/0001213900-26-112688.md) | Report of a foreign private issuer, period 2026-10-27 | 0001213900-26-112688 | | 2026-10-26 | 08:00 ET | [6-K](/filings/0001213900-26-112283.md) | Report of a foreign private issuer, period 2026-10-26 | 0001213900-26-112283 | | 2026-10-20 | 06:07 ET | [6-K](/filings/0001213900-26-110813.md) | Report of a foreign private issuer, period 2026-10-20 | 0001213900-26-110813 | | 2026-10-05 | 08:00 ET | [6-K](/filings/0001213900-26-106652.md) | Report of a foreign private issuer, period 2026-10-05 | 0001213900-26-106652 | | 2026-10-01 | 07:59 ET | [6-K](/filings/0001213900-26-105456.md) | Report of a foreign private issuer, period 2026-10-01 | 0001213900-26-105456 | | 2026-09-30 | 15:16 ET | [20-F](/filings/0001213900-26-105181.md) | Annual report of a foreign private issuer, period 2026-06-30 | 0001213900-26-105181 | | 2026-09-30 | 06:08 ET | [6-K](/filings/0001213900-26-104850.md) | Report of a foreign private issuer, period 2026-09-30 | 0001213900-26-104850 | | 2026-09-22 | 08:00 ET | [6-K](/filings/0001213900-26-101968.md) | Report of a foreign private issuer, period 2026-09-22 | 0001213900-26-101968 | | 2026-09-14 | 06:11 ET | [6-K](/filings/0001213900-26-099435.md) | Report of a foreign private issuer, period 2026-09-14 | 0001213900-26-099435 | | 2026-09-11 | 08:00 ET | [6-K](/filings/0001213900-26-098976.md) | Report of a foreign private issuer, period 2026-09-11 | 0001213900-26-098976 | ## Latest annual report [Form 20-F for the fiscal year ended Jun 30, 2026](/filings/0001213900-26-105181.md), filed Sep 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1949257 - Tickers: RADX, RDPTF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: C3 - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 08:01 ET. No prices; not investment advice.